Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 2Gynecologic 2Head & Neck 1Gastrointestinal 1Breast 1

Conditions

Neoplasm Metastasis 2Endometrial Neoplasms 2Bile Duct Neoplasms 2Stomach Neoplasms 1Salivary Gland Neoplasms 1Pancreatic Neoplasms 1Colorectal Neoplasms 1Colonic Neoplasms 1Cholangiocarcinoma 1Carcinosarcoma 1Carcinoma, Transitional Cell 1Carcinoma, Renal Cell 1Breast Neoplasms 1

Interventions

Specimen Handling 4Magnetic Resonance Spectroscopy 3Nivolumab 2Biopsy 2trastuzumab deruxtecan 1sargramostim 1rucaparib 1ribociclib 1pembrolizumab 1ceralasertib 1belinostat 1X-Rays 1Tissue Banks 1Ipilimumab 1Immunoglobulin G 1Fulvestrant 1Fluorouracil 1Cyclophosphamide 1Colony-Stimulating Factors 1Carboplatin 1CTLA-4 Antigen 1Blood Specimen Collection 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinosarcoma × ceralasertib × Gastrointestinal × Clear all
NCT04704661 2026-05-13

Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial

National Cancer Institute (NCI)

Phase 1 Active not recruiting
51 enrolled
BreastGastrointestinalGynecologicHead & NeckSarcoma

Breast Neoplasms, Carcinosarcoma, Colonic Neoplasms, Neoplasm Metastasis, Salivary Gland Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡